Vaccine equity refers to fair and impartial access to vaccines for all individuals, irrespective of their geographic location, socioeconomic status, or background. Achieving vaccine equity is crucial to effectively combatting infectious diseases on a global scale, ensuring that vulnerable populations are not left behind in the fight against illnesses.
This concept emphasizes the distribution of vaccines in a manner that prioritizes those most in need, acknowledging and addressing systemic barriers that hinder access to healthcare. By addressing factors such as affordability, infrastructure, education, and prioritizing marginalized communities, vaccine equity aims to create a level playing field where everyone has equal opportunities to receive life-saving vaccinations.
Efforts to promote vaccine equity involve collaborations among governments, healthcare organizations, pharmaceutical companies, and international bodies to develop strategies that guarantee fair vaccine distribution worldwide. This approach not only safeguards individual health but also contributes to global health security by reducing the risk of outbreaks and fostering a more resilient and healthier society. Achieving vaccine equity is a critical step towards building a more inclusive and healthier world for all.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States